Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters










Publication year range
1.
Proc Natl Acad Sci U S A ; 119(49): e2116220119, 2022 12 06.
Article in English | MEDLINE | ID: mdl-36459642

ABSTRACT

Rhabdomyosarcoma (RMS) is an aggressive pediatric soft-tissue cancer with features of skeletal muscle. Because of poor survival of RMS patients and severe long-term side effects of RMS therapies, alternative RMS therapies are urgently needed. Here we show that the prospero-related homeobox 1 (PROX1) transcription factor is highly expressed in RMS tumors regardless of their cell type of origin. We demonstrate that PROX1 is needed for RMS cell clonogenicity, growth and tumor formation. PROX1 gene silencing repressed several myogenic and tumorigenic transcripts and transformed the RD cell transcriptome to resemble that of benign mesenchymal stem cells. Importantly, we found that fibroblast growth factor receptors (FGFR) mediated the growth effects of PROX1 in RMS. Because of receptor cross-compensation, paralog-specific FGFR inhibition did not mimic the effects of PROX1 silencing, whereas a pan-FGFR inhibitor ablated RMS cell proliferation and induced apoptosis. Our findings uncover the critical role of PROX1 in RMS and offer insights into the mechanisms that regulate RMS development and growth. As FGFR inhibitors have already been tested in clinical phase I/II trials in other cancer types, our findings provide an alternative option for RMS treatment.


Subject(s)
Genes, Homeobox , Rhabdomyosarcoma , Humans , Child , Transcription Factors , Rhabdomyosarcoma/drug therapy , Rhabdomyosarcoma/genetics , Gene Expression Regulation , Receptors, Fibroblast Growth Factor , Transcriptome , Protein Kinase Inhibitors
2.
Tumour Biol ; 44(1): 69-84, 2022.
Article in English | MEDLINE | ID: mdl-35786664

ABSTRACT

BACKGROUND: Wnt/ß-catenin signaling is a highly conserved signaling pathway that regulates the transcription factor PROX1. The role of ß-catenin and PROX1 in pancreatic cancer is ambiguous, as some studies have associated their expression with tumor regression and some with tumor progression. OBJECTIVE: We have investigated their expression in surgically treated pancreatic cancer patients receiving neoadjuvant therapy (NAT), and patients treated upfront with surgery (US). We furthermore compared the expression of ß-catenin and PROX1 between patients who had a good or poor response to NAT. METHODS: We evaluated ß-catenin and PROX1 expression through immunohistochemistry in 88 neoadjuvant and 144 upfront surgery patients by scoring the intensity of the immunopositivity as 0-3, corresponding to negative, weak, moderate, or strong. We developed a six-tier grading scheme for the neoadjuvant responses by analyzing the remaining tumor cells in surgical specimen histological sections. RESULTS: Strong ß-catenin immunopositivity associated with improved survival in the patients with good NAT-response (≤10% residual tumor cells) (Hazard ratio [HR] 0.26 95%, confidence interval [CI] 0.07-0.88 p = 0.030). Additionally, the combined moderate ß-catenin and PROX1 expression associated with improved survival (HR 0.20 95% CI 0.05-0-76 p = 0.018) among the good responders. Among the patients with a poor NAT-response (> 10% residual tumor cells), both strong ß-catenin immunopositivity and strong combined ß-catenin and PROX1 associated with shorter survival (HR 2.03 95% CI 1.16-3.55 p = 0.013, and HR 3.1 95% CI 1.08-8.94 p = 0.03, respectively). PROX1 alone was not associated with survival. CONCLUSIONS: Strong ß-catenin immunopositivity and combined strong or moderate ß-catenin and PROX1 immunopositivity associated with improved survival among the good NAT-responders and worse survival among the poor NAT-responders.


Subject(s)
Pancreatic Neoplasms , beta Catenin , Disease Progression , Homeodomain Proteins , Humans , Neoadjuvant Therapy , Neoplasm, Residual , Pancreatic Neoplasms/pathology , Transcription Factors , Tumor Suppressor Proteins , Wnt Signaling Pathway , beta Catenin/metabolism , Pancreatic Neoplasms
3.
Gastroenterology ; 160(1): 245-259, 2021 01.
Article in English | MEDLINE | ID: mdl-32941878

ABSTRACT

BACKGROUND & AIMS: Mutations in the APC gene and other genes in the Wnt signaling pathway contribute to development of colorectal carcinomas. R-spondins (RSPOs) are secreted proteins that amplify Wnt signaling in intestinal stem cells. Alterations in RSPO genes have been identified in human colorectal tumors. We studied the effects of RSPO1 overexpression in ApcMin/+ mutant mice. METHODS: An adeno associated viral vector encoding RSPO1-Fc fusion protein, or control vector, was injected into ApcMin/+mice. Their intestinal crypts were isolated and cultured as organoids. which were incubated with or without RSPO1-Fc and an inhibitor of transforming growth factor beta receptor (TGFBR). Livers were collected from mice and analyzed by immunohistochemistry. Organoids and adenomas were analyzed by quantitative reverse-transcription PCR, single cell RNA sequencing, and immunohistochemistry. RESULTS: Intestines from Apc+/+ mice injected with the vector encoding RSPO1-Fc had significantly deeper crypts, longer villi, with increased EdU labeling, indicating increased proliferation of epithelial cells, in comparison to mice given control vector. AAV-RSPO1-Fc-transduced ApcMin/+ mice also developed fewer and smaller intestinal tumors and had significantly longer survival times. Adenomas of ApcMin/+ mice injected with the RSPO1-Fc vector showed a rapid increase in apoptosis and in the expression of Wnt target genes, followed by reduced expression of messenger RNAs and proteins regulated by the Wnt pathway, reduced cell proliferation, and less crypt branching than adenomas of mice given the control vector. Addition of RSPO1 reduced the number of adenoma organoids derived from ApcMin/+ mice and suppressed expression of Wnt target genes but increased phosphorylation of SMAD2 and transcription of genes regulated by SMAD. Inhibition of TGFBR signaling in organoids stimulated with RSPO1-Fc restored organoid formation and expression of genes regulated by Wnt. The TGFBR inhibitor restored apoptosis in adenomas from ApcMin/+ mice expressing RSPO1-Fc back to the same level as in the adenomas from mice given the control vector. CONCLUSIONS: Expression of RSPO1 in ApcMin/+ mice increases apoptosis and reduces proliferation and Wnt signaling in adenoma cells, resulting in development of fewer and smaller intestinal tumors and longer mouse survival. Addition of RSPO1 to organoids derived from adenomas inhibits their growth and promotes proliferation of intestinal stem cells that retain the APC protein; these effects are reversed by TGFB inhibitor. Strategies to increase the expression of RSPO1 might be developed for the treatment of intestinal adenomas.


Subject(s)
Adenoma/pathology , Intestinal Neoplasms/pathology , Thrombospondins/metabolism , Transforming Growth Factor beta/physiology , Wnt Signaling Pathway/physiology , Adenoma/etiology , Animals , Disease Models, Animal , Intestinal Neoplasms/etiology , Mice , Organoids
4.
Cancer Res ; 80(12): 2639-2650, 2020 06 15.
Article in English | MEDLINE | ID: mdl-32312835

ABSTRACT

Abnormal vasculature in tumors leads to poor tissue perfusion and cytostatic drug delivery. Although drugs inducing vascular normalization, for example, angiopoietin-2 (Ang2)-blocking antibodies, have shown promising results in preclinical tumor models, clinical studies have so far shown only little efficacy. Because Ang2 is known to play a protective role in stressed endothelial cells, we tested here whether Ang2 blocking could enhance radiation-induced tumor vascular damage. Tumor-bearing mice were treated with anti-Ang2 antibodies every 3 or 4 days starting 3 days before 3 × 2 Gy or 4 × 0.5 Gy whole-body or tumor-focused radiation. Combination treatment with anti-Ang2 and radiation improved tumor growth inhibition and extended the survival of mice with melanoma or colorectal tumors. Single-cell RNA-sequencing revealed that Ang2 blocking rescued radiation-induced decreases in T cells and cells of the monocyte/macrophage lineage. In addition, anti-Ang2 enhanced radiation-induced apoptosis in cultured endothelial cells. In vivo, combination treatment decreased tumor vasculature and increased tumor necrosis in comparison with tumors treated with monotherapies. These results suggest that a combination of Ang2-blocking antibodies with radiation increases tumor growth inhibition and extends the survival of tumor-bearing mice. SIGNIFICANCE: These findings offer a preclinical rationale for further testing of the use of radiation in combination with Ang2-blocking antibodies to improve the overall outcome of cancer treatment.


Subject(s)
Angiogenesis Inhibitors/administration & dosage , Angiopoietin-2/antagonists & inhibitors , Chemoradiotherapy/methods , Colorectal Neoplasms/therapy , Melanoma, Experimental/therapy , Neovascularization, Pathologic/therapy , Animals , Apoptosis/drug effects , Apoptosis/radiation effects , Cell Line, Tumor , Colorectal Neoplasms/pathology , Endothelial Cells , Female , Humans , Male , Melanoma, Experimental/pathology , Mice , Neovascularization, Pathologic/pathology , RNA-Seq , Single-Cell Analysis , Tumor Microenvironment/drug effects , Tumor Microenvironment/radiation effects , Xenograft Model Antitumor Assays
5.
Cancer Res ; 78(20): 5820-5832, 2018 10 15.
Article in English | MEDLINE | ID: mdl-30154153

ABSTRACT

The homeobox transcription factor PROX1 is induced by high Wnt/ß-catenin activity in intestinal adenomas and colorectal cancer, where it promotes tumor progression. Here we report that in LGR5+ colorectal cancer cells, PROX1 suppresses the Notch pathway, which is essential for cell fate in intestinal stem cells. Pharmacologic inhibition of Notch in ex vivo 3D organoid cultures from transgenic mouse intestinal adenoma models increased Prox1 expression and the number of PROX1-positive cells. Notch inhibition led to increased proliferation of the PROX1-positive colorectal cancer cells, but did not affect their ability to give rise to PROX1-negative secretory cells. Conversely, PROX1 deletion increased Notch target gene expression and NOTCH1 promoter activity, indicating reciprocal regulation between PROX1 and the Notch pathway in colorectal cancer. PROX1 interacted with the nucleosome remodeling and deacetylase (NuRD) complex to suppress the Notch pathway. Thus, our data suggests that PROX1 and Notch suppress each other and that PROX1-mediated suppression of Notch mediates its stem cell function in colorectal cancer.Significance: These findings address the role of the PROX1 homeobox factor as a downstream effector of Wnt/ß-catenin singling in colorectal cancer stem cells and show that PROX1 inhibits the Notch pathway and helps to enforce the stem cell phenotype and inhibit differentiation. Cancer Res; 78(20); 5820-32. ©2018 AACR.


Subject(s)
Colorectal Neoplasms/metabolism , Homeodomain Proteins/genetics , Homeodomain Proteins/metabolism , Neoplastic Stem Cells/metabolism , Nucleosomes/metabolism , Receptors, Notch/metabolism , Tumor Suppressor Proteins/genetics , Tumor Suppressor Proteins/metabolism , Adenoma/metabolism , Animals , Cell Line, Tumor , Cell Lineage , Cell Proliferation , Crosses, Genetic , Female , Genes, Homeobox , HEK293 Cells , Humans , Intestines/pathology , Male , Mice , Mice, Transgenic , Oligonucleotide Array Sequence Analysis , Organ Culture Techniques , Receptors, Notch/antagonists & inhibitors , Sequence Analysis, RNA
6.
PLoS One ; 12(8): e0183868, 2017.
Article in English | MEDLINE | ID: mdl-28854215

ABSTRACT

BACKGROUND: PROX1 is a transcription factor involved in the development of various organs. It has also an important function in colorectal cancer progression. The aim of this study was to investigate the prognostic role of PROX1 expression in gastric cancer. METHODS: We evaluated PROX1 expression in gastric cancer by immunohistochemistry of tumor-tissue microarrays including tumor specimens from 283 patients who underwent surgery at Helsinki University Hospital. We investigated the association of PROX1 expression with clinicopathologic variables and patient survival. RESULTS: Cytoplasmic PROX1 reactivity was high in 56 (20.5%) and low in 217 (79.5%) cases. Low PROX1 immunostaining associated with diffuse cancer type (p = 0.002). In subgroup analysis, PROX1 was a significant marker of better prognosis in patients aged under 66 (p = 0.007), in those with intestinal cancer (p = 0.025), among men (p = 0.019), and in tumors of less than 5 cm diameter (p = 0.030). Patients with high PROX1 expression had a cancer-specific 5-year survival of 65.6% (95% CI 52.7-78.5), compared to 37.1% (95% CI 30.2-44.0) for those with low expression (p = 0.004, log-rank test). This result remained significant in multivariable analysis (HR = 0.56; 95% CI 0.35-0.90; p = 0.017). CONCLUSION: In gastric cancer, high cytoplasmic PROX1 expression is an independent marker of better prognosis.


Subject(s)
Adenocarcinoma/diagnosis , Homeodomain Proteins/analysis , Stomach Neoplasms/diagnosis , Stomach/pathology , Tumor Suppressor Proteins/analysis , Adenocarcinoma/pathology , Adenocarcinoma/surgery , Aged , Biomarkers, Tumor/analysis , Female , Humans , Immunohistochemistry , Kaplan-Meier Estimate , Male , Middle Aged , Prognosis , Proportional Hazards Models , Stomach/surgery , Stomach Neoplasms/pathology , Stomach Neoplasms/surgery
7.
BMC Cancer ; 16: 472, 2016 07 13.
Article in English | MEDLINE | ID: mdl-27411302

ABSTRACT

BACKGROUND: The Wnt/ß-catenin pathway has a key role in regulating cellular processes and its aberrant signaling can lead to cancer development. The role of ß-catenin expression in pancreatic ductal adenocarcinoma is somewhat controversial. Transcription factor PROX1 is a target of Wnt/ß-catenin signaling and it is involved in carcinogenesis through alterations in its expression. The actions can be either oncogenic or tumor suppressive depending on the tissue. The aim of this study was to investigate PROX1 and ß-catenin expression in pancreatic ductal adenocarcinoma (PDAC). METHODS: Expression of PROX1 and ß-catenin were evaluated in 156 patients by immunohistochemistry of tissue microarrays. Associations between tumor marker expression and clinicopathological parameters were assessed by the Fischer's exact-test or the linear-by-linear association test. The Kaplan-Meier method and log-rank test were used for survival analysis. Uni- and multivariate survival analyses were carried out by the Cox regression proportional hazard model. RESULTS: High PROX1 expression was seen in 74 (48 %) tumors, and high ß-catenin expression in 100 (65 %). High ß-catenin expression was associated with lower tumor grade (p = 0.025). High PROX1 and ß-catenin expression associated significantly with lower risk of death from PDAC in multivariate analysis (HR = 0.63; 95 % CI 0.42-0.95, p = 0.026; and HR = 0.54; 95 % CI 0.35-0.82, p = 0.004; respectively). The combined high expression of PROX1 and ß-catenin also predicted lower risk of death from PDAC (HR = 0.46; 95 % CI 0.28-0.76, p = 0.002). CONCLUSION: In conclusion, high PROX1 and ß-catenin expression were independent factors for better prognosis in pancreatic ductal adenocarcinoma.


Subject(s)
Carcinoma, Pancreatic Ductal/mortality , Carcinoma, Pancreatic Ductal/pathology , Homeodomain Proteins/metabolism , Pancreatic Neoplasms/mortality , Pancreatic Neoplasms/pathology , Tumor Suppressor Proteins/metabolism , beta Catenin/metabolism , Adult , Aged , Aged, 80 and over , Biomarkers, Tumor/metabolism , Carcinoma, Pancreatic Ductal/metabolism , Carcinoma, Pancreatic Ductal/surgery , Female , Humans , Immunohistochemistry , Kaplan-Meier Estimate , Male , Middle Aged , Neoplasm Staging , Pancreatic Neoplasms/metabolism , Pancreatic Neoplasms/surgery , Prognosis , Proportional Hazards Models , Retrospective Studies , Tissue Array Analysis , Wnt Signaling Pathway
8.
Virchows Arch ; 467(3): 279-84, 2015 Sep.
Article in English | MEDLINE | ID: mdl-26063416

ABSTRACT

PROX1 is a homeobox transcription factor involved in the development of the lens, liver and heart and found upregulated in colorectal cancers. We studied PROX1 expression by immunohistochemistry in rectal neuroendocrine tumors (NETs). Approximately 10 to 15 % of gastroenteropancreatic NETs occur in the rectum, and some may metastasize. Yet little is known about the molecular pathogenesis of rectal NETs or their metastasis propensity. The objectives were to find out whether PROX1 plays a role in progression of rectal NETs and whether it has value as prognostic marker. In grading of rectal NETs, we applied the WHO 2010 classification. We carried out immunohistochemical staining of PROX1 on 72 primary tumors and six metastases and evaluated nuclear positivity in each tumor. Correlation between PROX1 expression, metastasis and patient survival was then assessed. Annexin A1, a downstream target of PROX1, was immunohistochemically assessed in 18 tumors. PROX1 protein was detected in about half of the tumors, with stronger expression in metastasized cases. PROX1 expression correlated with tumor metastasis and patient prognosis. Annexin A1 was negative in most of the high-grade tumors correlating strongly with grade and metastatic potential. Our results indicate that immunohistochemical detection of PROX1 correlates with a more malignant phenotype in rectal NETs. High PROX1 expression was associated with increased metastatic potential and poor patient survival but not as strongly as grade by the WHO 2010 classification. PROX1 may be involved in progression of rectal NETs as a part of the Wnt pathway.


Subject(s)
Biomarkers, Tumor/analysis , Homeodomain Proteins/metabolism , Neuroendocrine Tumors/pathology , Rectal Neoplasms/pathology , Tumor Suppressor Proteins/metabolism , Disease Progression , Female , Homeodomain Proteins/analysis , Humans , Immunohistochemistry , Male , Middle Aged , Tumor Suppressor Proteins/analysis
9.
Cell Rep ; 8(6): 1943-1956, 2014 Sep 25.
Article in English | MEDLINE | ID: mdl-25242330

ABSTRACT

Colorectal cancer (CRC) initiation and growth is often attributed to stem cells, yet little is known about the regulation of these cells. We show here that a subpopulation of Prox1-transcription-factor-expressing cells have stem cell activity in intestinal adenomas, but not in the normal intestine. Using in vivo models and 3D ex vivo organoid cultures of mouse adenomas and human CRC, we found that Prox1 deletion reduced the number of stem cells and cell proliferation and decreased intestinal tumor growth via induction of annexin A1 and reduction of the actin-binding protein filamin A, which has been implicated as a prognostic marker in CRC. Loss of Prox1 also decreased autophagy and the survival of hypoxic tumor cells in tumor transplants. Thus, Prox1 is essential for the expansion of the stem cell pool in intestinal adenomas and CRC without being critical for the normal functions of the gut.


Subject(s)
Homeodomain Proteins/metabolism , Neoplastic Stem Cells/metabolism , Tumor Suppressor Proteins/metabolism , Animals , Annexin A1/antagonists & inhibitors , Annexin A1/genetics , Annexin A1/metabolism , Autophagy , Cell Culture Techniques , Cell Hypoxia , Cell Line, Tumor , Cell Proliferation , Colorectal Neoplasms/metabolism , Colorectal Neoplasms/pathology , Filamins/antagonists & inhibitors , Filamins/genetics , Filamins/metabolism , Homeodomain Proteins/antagonists & inhibitors , Homeodomain Proteins/genetics , Humans , Ischemia/pathology , Ischemia/prevention & control , Mice , Mice, Inbred C57BL , Neoplastic Stem Cells/cytology , RNA Interference , RNA, Small Interfering/metabolism , Receptors, G-Protein-Coupled/metabolism , Transplantation, Heterologous , Tumor Suppressor Proteins/antagonists & inhibitors , Tumor Suppressor Proteins/genetics , Up-Regulation
10.
Proc Natl Acad Sci U S A ; 111(21): E2229-36, 2014 May 27.
Article in English | MEDLINE | ID: mdl-24825889

ABSTRACT

In the majority of microsatellite-stable colorectal cancers (CRCs), an initiating mutation occurs in the adenomatous polyposis coli (APC) or ß-catenin gene, activating the ß-catenin/TCF pathway. The progression of resulting adenomas is associated with oncogenic activation of KRas and inactivation of the p53 and TGF-ß/Smad functions. Most established CRC cell lines contain mutations in the TGF-ß/Smad pathway, but little is known about the function of TGF-ß in the early phases of intestinal tumorigenesis. We used mouse and human ex vivo 3D intestinal organoid cultures and in vivo mouse models to study the effect of TGF-ß on the Lgr5(+) intestinal stem cells and their progeny in intestinal adenomas. We found that the TGF-ß-induced apoptosis in Apc-mutant organoids, including the Lgr5(+) stem cells, was mediated by up-regulation of the BH3-only proapoptotic protein Bcl-2-like protein 11 (Bim). BH3-mimetic compounds recapitulated the effect of Bim not only in the adenomas but also in human CRC organoids that had lost responsiveness to TGF-ß-induced apoptosis. However, wild-type intestinal crypts were markedly less sensitive to TGF-ß than Apc-mutant adenomas, whereas the KRas oncogene increased resistance to TGF-ß via the activation of the Erk1/2 kinase pathway, leading to Bim down-regulation. Our studies identify Bim as a critical mediator of TGF-ß-induced apoptosis in intestinal adenomas and show that the common progression mutations modify Bim levels and sensitivity to TGF-ß during intestinal adenoma development.


Subject(s)
Adenoma/genetics , Apoptosis Regulatory Proteins/metabolism , Apoptosis/genetics , Gene Expression Regulation, Neoplastic/genetics , Intestinal Neoplasms/genetics , Membrane Proteins/metabolism , Proto-Oncogene Proteins/metabolism , Transforming Growth Factor beta/metabolism , Animals , Bcl-2-Like Protein 11 , Blotting, Western , Cells, Cultured , Chromatography, Gel , DNA Primers/genetics , Flow Cytometry , Humans , Mice , Microarray Analysis , Organoids/metabolism , Receptors, G-Protein-Coupled/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Stem Cells/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...